Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

878
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
878
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WNK-SPAK/OSR1 signaling pathway facilitates ictal activity via reduced neuronal chloride extrusion rate.

bioRxiv : the preprint server for biology·2026
Same author

Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine: A Case Series.

Chest·2026
Same author

Correction: Normoyle et al. Synthesis and Characterization of a Novel Concentration-Independent Fluorescent Chloride Indicator, ABP-Dextran, Optimized for Extracellular Chloride Measurement. <i>Biomolecules</i> 2024, <i>14</i>, 77.

Biomolecules·2026
Same author

Deep Learning Discriminates Seizures from Normal Brain Oscillations in the Electroencephalogram of a Rat Model of Post-traumatic Epilepsy.

eNeuro·2026
Same author

In vivo tau in epilepsy reflects clinical severity and immune- and ageing-related proteomic changes.

Brain : a journal of neurology·2026
Same author

First sequence-verified detection of Perkinsus chesapeaki in Pacific oysters (Magallana gigas) from South Korea.

Journal of invertebrate pathology·2026

Related Experiment Video

Updated: Mar 8, 2026

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.6K

Staged anticonvulsant screening for chronic epilepsy.

Yevgeny Berdichevsky1, Yero Saponjian2, Kyung-Il Park3

  • 1Department of Electrical and Computer Engineering and Bioengineering Program Lehigh University Bethlehem Pennsylvania 18015.

Annals of Clinical and Translational Neurology
|January 19, 2017
PubMed
Summary

A new tiered screening program identified celecoxib as an effective anticonvulsant for chronic epilepsy. This approach, using organotypic hippocampal cultures, successfully found treatments missed by traditional methods.

More Related Videos

Performing Behavioral Tasks in Subjects with Intracranial Electrodes
12:10

Performing Behavioral Tasks in Subjects with Intracranial Electrodes

Published on: October 2, 2014

11.9K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

20.1K

Related Experiment Videos

Last Updated: Mar 8, 2026

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.6K
Performing Behavioral Tasks in Subjects with Intracranial Electrodes
12:10

Performing Behavioral Tasks in Subjects with Intracranial Electrodes

Published on: October 2, 2014

11.9K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

20.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Current anticonvulsant drug discovery relies on models using induced seizures in normal animals.
  • A significant portion of epilepsy patients (one-third) exhibit drug resistance to treatments identified through these conventional models.
  • There is a critical need for novel screening strategies to identify effective anticonvulsants for treatment-resistant epilepsy.

Purpose of the Study:

  • To evaluate a novel tiered screening program for anticonvulsant discovery.
  • To investigate compounds using a model of chronic epilepsy with spontaneous seizures.
  • To compare the efficacy of compounds identified through this tiered approach against traditional screening methods.

Main Methods:

  • A tiered program was employed, starting with high-throughput in vitro models and progressing to low-throughput in vivo models.
  • Organotypic hippocampal slice cultures were used to quantify epileptogenesis via lactate production and lactate dehydrogenase release.
  • Compounds showing promise were further tested using in vitro electrophysiology and the kainate model of chronic epilepsy for spontaneous seizure analysis.

Main Results:

  • The study screened 407 compound-concentration combinations.
  • Celecoxib, a cyclooxygenase inhibitor, showed no effect on seizures in normal brain tissue models.
  • Celecoxib demonstrated significant antiseizure activity across all tested models of chronic epilepsy.

Conclusions:

  • Organotypic hippocampal cultures enable rapid screening of compounds in chronic epilepsy models by compressing the time scale of epileptogenesis.
  • Biomarker assays for seizure-like activity and cell death in these cultures overcome throughput limitations of traditional in vivo models.
  • This innovative screening strategy successfully identified an anticonvulsant (celecoxib) that traditional acute models would likely miss, offering a new avenue for drug discovery in resistant epilepsy.